KOSDAQElectronic Components234920

Zaigle

₩5,310 0.00%2026-11-18 close
Market Cap
₩71.8B
Turnover
₩0
Volume
0 shares
Shares out.
13.5M
PER
156.2×
PBR
3.4×
EPS
₩34
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue rebound and first profit quarters, but the deficit history still weighs

Zaigle's revenue has risen for four straight quarters through Q3 2026 and operating profit has been positive since Q2 2026, but four years of losses from 2022 to 2025 and a shrinking equity base still define the balance sheet.

  1. 1

    Revenue recovery: Q3 2026 revenue of KRW 3.85 billion was up 122.1% year on year from KRW 1.73 billion in Q3 2025.

  2. 2

    Operating profit turned positive: operating profit of KRW 721 million in Q2 2026 was followed by KRW 1.06 billion in Q3, the second consecutive profitable quarter.

  3. 3

    Annual losses persist: the 2025 operating loss was KRW 3.66 billion and the net loss attributable to controlling shareholders was KRW 5.37 billion, the fourth straight year of losses since 2022.

  4. 4

    Balance sheet pressure: the debt-to-equity ratio was 158.9% at end-2025, with total equity of KRW 19.2 billion and total liabilities of KRW 30.5 billion.

  5. 5

    Ownership and liquidity: the largest shareholder group holds 68.24%, and the free float ratio is 30.98% (as of September 30, 2026).

02

Business structure

Zaigle is a kitchen and healthcare appliance maker founded in 2008. Its core product is the top-heating infrared cooker 'Zaigle Grill', and the company develops and manufactures grills, ovens and griddles built on infrared heating technology.

The product line that smoke- and odor-reducing design built is the starting point, and it sold strongly through Korean home shopping channels. Later the company widened into oxygen and high-frequency medical devices as it pursued a shift toward a healthcare specialist.

In March 2023 the 'Zaigle ON medical device' received a Class 3 medical device approval from the Ministry of Food and Drug Safety, and the high-frequency device 'Nest' launched in April 2023.

In December 2025 new home-care products were launched, including the high-frequency facial care device 'Zaigle ON Silk' and the abdominal massager 'Zaigle ON Cell375'. Sales run mainly through home shopping, duty-free stores and the company's own online channels.

An external data aggregator classifies Q2 2026 revenue under a single segment, wellbeing appliances (healthcare).

In December 2022 the company acquired domestic LFP battery production assets for about KRW 7.4 billion and entered secondary batteries, but after taking a 30% stake in the US joint venture ZAICELL in July 2023, the in-kind contribution and share acquisition were fully cancelled in December 2024, and the business was reported as effectively halted.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.7B-₩1B−59.0%
2025Q4₩2.2B-₩500M−22.1%
2026Q1₩2.5B-₩500M−19.9%
2026Q2₩2.7B₩700M26.5%
2026Q3₩3.9B₩1.1B27.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩15B-₩2.7B-₩3.7B−17.7%−9.0%46.4%
2023₩4.1B-₩8.7B-₩10.4B−209.1%−33.1%65.1%
2024₩12.1B-₩4.9B-₩6.8B−40.5%−27.5%122.3%
2025₩8.2B-₩3.7B-₩5.4B−44.4%−28.0%158.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue fell from KRW 15 billion in 2022 to KRW 4.14 billion in 2023 (down 72.4% year on year), recovered to KRW 12.1 billion in 2024 (up 191.3%), and then declined to KRW 8.23 billion in 2025 (down 31.8%). Among 2022 to 2025, 2022 was the largest year and 2023 the smallest.

Operating losses were KRW 2.65 billion in 2022, KRW 8.67 billion in 2023, KRW 4.89 billion in 2024 and KRW 3.66 billion in 2025, marking four consecutive years of operating losses. In 2023, the year with the largest loss, revenue was at its lowest and the operating margin fell to -209.1%.

The 2025 operating loss narrowed from 2024, yet the operating margin was -44.4% against -40.5% in 2024, so the revenue decline weighed heavily.

The net loss attributable to controlling shareholders widened from KRW 3.74 billion in 2022 to KRW 10.4 billion in 2023, then narrowed to KRW 6.77 billion in 2024 and KRW 5.37 billion in 2025, and the net loss including non-controlling interests was recorded at the same amounts.

Operating cash flow was -KRW 829 million in 2022, -KRW 6.34 billion in 2023, -KRW 4.25 billion in 2024 and -KRW 6.79 billion in 2025, negative in all four years.

The debt-to-equity ratio rose from 46.4% in 2022 to 158.9% in 2025, with total equity of KRW 19.2 billion and total liabilities of KRW 30.5 billion at end-2025. Quarterly revenue rose for four consecutive quarters, from KRW 1.73 billion in Q3 2025 to KRW 3.85 billion in Q3 2026, and Q3 2026 was up 122.1% year on year.

Operating results were losses from Q3 2025 through Q1 2026, with an operating loss of KRW 502 million in Q1 2026, before Q2 2026 turned to an operating profit of KRW 721 million, and Q3 2026 reached KRW 1.06 billion, up 46.5% from the prior quarter.

Gross margin in Q1 2026 rose from 42.0% to 73.4% as cost of sales fell by more than half while revenue grew 8.0% year on year, according to an analysis of the quarterly report.

That analysis argued that the durability of the profit turn depends on whether the cost gain came from sustainable manufacturing and purchasing improvements rather than product mix or inventory sales.

Net income attributable to controlling shareholders turned positive at KRW 167 million in Q1 2026, then rose to KRW 597 million in Q2 and KRW 826 million in Q3, and the four-quarter total from Q4 2025 to Q3 2026 was KRW 459 million.

Whether one-off items such as asset sale proceeds or litigation proceeds affected quarterly profit should be checked against the detailed items in the next periodic report.

05

Industry analysis

Under the Korea Exchange classification Zaigle sits in the KOSDAQ electrical and electronics sector, but its core products are kitchen cookers and household healthcare devices, so its earnings model differs from component makers in the same sector such as Samsung Electro-Mechanics and LG Innotek.

In kitchen appliances, the company positions its top-down infrared cooking method as its point of difference. Distribution centered on home shopping and duty-free retail tends to make revenue swing with how new products sell.

The healthcare line includes devices approved by the Ministry of Food and Drug Safety, which follow approval requirements different from those for kitchen appliances.

In secondary batteries, LFP cell prices have settled low under Chinese producers and large Korean firms are also entering, so a newcomer may face price competition, a view raised by industry participants. One report noted that industry sources treated the success of Zaigle's battery business as uncertain.

A June 2025 share price surge was attributed to the stock being grouped with secondary battery themes on expectations tied to Tesla's robotaxi plans. Research and development spending as a share of revenue fell from 6.97% in 2024 to 4.22% in 2025 and 2.84% in Q1 2026.

A securities industry source has noted that the shares tend to react to new-business keywords and that actual progress in new businesses should be checked carefully.

Because the scale and profitability gap with larger component makers in the same sector is wide, reading the company's own earnings trend is more appropriate than direct comparison.

06

Outlook

This outlook is organized around the quarterly trend in reported results and the checkpoints that the company and the press have highlighted.

A report dated July 29, 2026 pointed to five Q2 checkpoints: keeping gross margin in the 73% range, a turn to operating profit, repayment or refinancing of maturing borrowings, use of proceeds from real estate sales, and collection of litigation proceeds.

Of these, the operating profit turn was delivered in Q2 with KRW 721 million, followed by KRW 1.06 billion in Q3. Whether gross margin holds near the Q1 2026 level of 73.4% will show whether the cost gains are durable.

The healthcare pipeline includes 'Zaigle ON Silk' and 'Cell375', launched in December 2025, and whether this line adds to the four-quarter revenue growth is the item to watch.

The secondary battery business is uncertain after the share acquisition was cancelled in December 2024, and in 2025 the company said it would disclose through filings once the business moved forward concretely.

Follow-up to the listing eligibility review, which was extended in November 2025, should be confirmed through company filings. Also to be watched is how asset sales and debt repayment are reflected in financial statements after Q4 2026.

The company's annual earnings targets are not set out in a form that can be carried into this report, so the outlook is framed around reported results and scheduled filings. The direction of annual operating profit and operating cash flow will be confirmed in the 2026 annual report, the next periodic report.

07

Valuation

PER
156.2×
PBR
3.4×
ROE
2.2%
EPS
₩34
BPS
₩1,548
Dividend per share
₩0

Zaigle's valuation should be read against a long run of losses. The price-to-earnings ratio stays high even after the Q2 2026 profit turn because earnings remain small, which suggests the earnings base is still thin.

The price-to-book ratio sits at a premium to net asset value, with total equity down to KRW 19.2 billion at end-2025. The dividend yield is below the sector average.

The shares rose sharply in the short term when new businesses were announced in 2023, so there have been periods when the price responded to themes more than to earnings. The largest shareholder group holds 68.24% and the free float is 30.98%, so the trading structure can influence price moves.

Because losses have lasted for years, a simple comparison with listed peers in the same sector has limited meaning. The key item to watch for the valuation read is whether operating profit stays positive in Q4 2026, which would widen the earnings base.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Quarterly revenue growth for four straight quarters

Revenue has increased for four consecutive quarters from Q4 2025 through Q3 2026, and Q3 2026 revenue of KRW 3.85 billion was up 122.1% year on year. Quarter-on-quarter growth has been uneven, at 28.0% in Q4 2025, 13.4% in Q1 2026, 8.2% in Q2 and 41.4% in Q3.

The continuity of the recovery across quarters is the main bull argument. Annual revenue of KRW 8.23 billion in 2025 is still below KRW 15 billion in 2022.

Operating profit turn and gross margin improvement

Operating profit was KRW 721 million in Q2 2026, a turn to profit, and KRW 1.06 billion in Q3. Gross margin in Q1 2026 rose from 42.0% to 73.4% as cost of sales fell by more than half while revenue grew 8.0%. If the cost improvement persists, the base for operating profit widens, which is the main bull reading. Whether the improvement came from temporary inventory sales still needs to be separated out.

Expansion of the healthcare product line

In March 2023 the 'Zaigle ON medical device' received a Class 3 medical device approval from the Ministry of Food and Drug Safety, and the high-frequency device 'Nest' launched in April 2023. In December 2025 new high-frequency facial and abdominal care devices came out.

Extending a business centered on kitchen appliances into approved healthcare products is the bull-side point. Revenue contribution from the new products is not separated in reported results, so the effect must be confirmed in later quarters.

09

Bear factors

Four straight years of operating losses and cash outflows

Operating losses have run for four consecutive years from 2022 through 2025, and the net loss attributable to controlling shareholders persisted over the same period. Operating cash flow was negative in all four years, and the 2025 outflow of -KRW 6.79 billion was larger than the -KRW 4.25 billion in 2024.

The 2025 operating loss narrowed to KRW 3.66 billion, but the operating margin worsened to -44.4% from -40.5%. Until quarterly profits change the annual loss pattern, the structural burden remains the main bear argument.

Shrinking equity and higher debt burden

The debt-to-equity ratio climbed each year from 46.4% in 2022 to 65.1% in 2023, 122.3% in 2024 and 158.9% in 2025. Total equity was KRW 19.2 billion and total liabilities were KRW 30.5 billion at end-2025. With equity shrinking while debt rose, the financial cushion has thinned.

Repayment or refinancing of maturing borrowings and the use of real estate sale proceeds are the variables that will determine the debt burden.

Secondary battery setback and disclosure credibility concerns

The company entered new business in December 2022 by acquiring LFP battery assets, but in December 2024 the in-kind contribution and share acquisition tied to the US joint venture were fully cancelled. In January 2025 it was designated an insincere disclosure company after the agreement with ZAICELL was withdrawn.

Press coverage pointed out that actual progress in the new business had not been verified after the announcements. Because the share price has moved on new-business expectations, disclosure credibility is cited as a bear factor.

10

Risk factors

Listing eligibility

The Korea Exchange extended the listing eligibility review period by 15 days in November 2025, and a decision on whether the company would be subject to a formal review was reported as due by December 10. Follow-up results should be confirmed through company filings. Periodic disclosures have continued through Q3 2026. Trading conditions could change significantly depending on the outcome, making this the largest risk item.

Ownership and liquidity

The largest shareholder group holds 68.24% of common shares, and the free float ratio is 30.98% as of September 30, 2026. Treasury shares account for 0.78%. With limited float, the share price can move sharply on small trades.

Because the largest shareholder's decision weight is high, transparency of management decisions is an important issue.

Business credibility and investment capacity

Research and development spending in Q1 2026 was 2.84% of revenue, down from 6.97% in 2024 and 4.22% in 2025. Whether healthcare R&D investment is maintained while asset sales and marketing expansion proceed is the key issue.

After the joint venture structure was cancelled, a concrete restart plan for the secondary battery business has not been disclosed. In 2025 the company said it would disclose through filings once the business moved forward concretely.

11

What to watch next

  1. December 31, 2026

    This is the close of the 2026 fiscal year. Whether the operating profit of Q2 and Q3 continues into Q4 will determine the direction of full-year operating results.

  2. Mid-March 2027 (estimated from the March 16, 2026 filing date of the prior annual report)

    This is when the 2026 annual report is expected to be filed. It will show whether annual revenue, operating results, the debt-to-equity ratio and operating cash flow have departed from four years of losses and negative cash flow.

  3. First half of 2027 (date not fixed)

    This is the point to check whether the secondary battery business restarts and whether follow-up filings on ZAICELL appear. Since the company said it would disclose concrete progress, the content of those filings will be the measure of whether the business is real.

12

Overall view

Zaigle's 2026 disclosures stand out for a revenue recovery and an operating profit turn arriving together. Revenue rose for four straight quarters from Q4 2025 through Q3 2026, and operating profit has been positive for two quarters since Q2 2026.

However, operating and net losses attributable to controlling shareholders ran for four consecutive years from 2022 through 2025, and operating cash flow was negative over the same period. The debt-to-equity ratio was 158.9% at end-2025, with total equity of KRW 19.2 billion, so financial cushion is thin.

The secondary battery business is uncertain after the share acquisition was cancelled and the insincere disclosure designation was made.

Bull factors are the healthcare product line and the Q1 2026 gross margin gain, while bear factors are the long loss record, the shrinking equity base, and uncertainty over governance and liquidity.

The next checkpoints are whether operating profit stays positive in Q4 2026 and what the annual cash flow shows in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. saramin.co.kr
  3. abcn.kr
  4. comp.wisereport.co.kr
  5. infostockdaily.co.kr
  6. sidae.com
  7. ajunews.com
  8. app.rndcircle.io
  9. m.ekn.kr
  10. businessreport.kr
  11. comp.fnguide.com
  12. alphasquare.co.kr
  13. sateconomy.co.kr
  14. butler.works
  15. kind.krx.co.kr
  16. jobkorea.co.kr
  17. news.samsung.com
  18. news.samsung.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis